{"name":"Korean Breast Cancer Study Group","slug":"korean-breast-cancer-study-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Paclitaxel loaded Polymeric micelle","genericName":"Paclitaxel loaded Polymeric micelle","slug":"paclitaxel-loaded-polymeric-micelle","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Paclitaxel loaded Polymeric micelle","genericName":"Paclitaxel loaded Polymeric micelle","slug":"paclitaxel-loaded-polymeric-micelle","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNY3JsX2lwZTZIZmh4TGI3RGFQVDlTeTMtanZMQmFaLXp5dGtxaUhlSVhJMzV0R2hselJ2aUpoUzZUNWxnYzZ6cjdMZGRDWV93OGhBd2k3dTZ1OGczQ054YVFURUhMUkktNV9TTEE5QUx6T2l1bDNZQmxQdW15UDdvQdIBlAFBVV95cUxQWVB3NUhoN0xWVXhIWkg4M29RV2FlcFFmZHhzM1IxVjdUWnctQnowLTZ6NUJiZUs5TnRrUVRpdlV0bU5qWmpyV2pIZDhENS13NXphS1RwNHg3MTkzdEVxWDF2TktuTWhIam1sNUFpVE1lS09EaVhTRmY0MHhTYTFxSG1HRXY0SzRWUEdBZXBUaVFYSE5i?oc=5","date":"2026-02-05","type":"pipeline","source":"Chosunbiz","summary":"Enhertu reshapes South Korea’s breast cancer treatment with ADC efficacy - CHOSUNBIZ - Chosunbiz","headline":"Enhertu reshapes South Korea’s breast cancer treatment with ADC efficacy - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE84UFA0UnJBNWpTSUdFSXZfVF9ucS14NjQzMHRTUWxndjlUc29oNDBIakZTWjJ2bWk4RkdSbklSMHRDSi1UTzcwWXpybU9PMjVTU2N5dG9hTTIxT1dmRm5oTXBmX191Ym5Eb2dBZlBn0gFyQVVfeXFMTnM0Y1dmOXhqa0hnU1RQOVUwVWJkTGxaNzg0am1vbU5FZzRHbk5lN3NHRHJWNWFUbENEZGZIcFg5XzFadW1XNXpIaW5FUUI3RHZSTkJUdlNYUHc3d3lrOWs4WHZWWGNERDhEVmI0WDV3V25n?oc=5","date":"2026-01-20","type":"regulatory","source":"koreabiomed.com","summary":"Enhertu wins Korean approval for HER2-low and HER2-ultra-low metastatic breast cancer - koreabiomed.com","headline":"Enhertu wins Korean approval for HER2-low and HER2-ultra-low metastatic breast cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5GZ0FDdS1RQnRpRC1uX184LURLWEJzbWJXZVpqd0tvU0JpNlhVelpldWVtVTg2OTNYdmZ0MkdXaTFiN2JlUFJKYjhfZ3MySVU1ZHJHS1hoa1N1QzNRYkdWay04TlRsVlVEZGFWSVpR0gFyQVVfeXFMTnBMU1IxRHIzYnJaZ1dLbnJRTTd0N2VuWk9oVk9xbkxwS05DcktEeHVRcmVsZzdWOHdSZEJHZ09wSC1aRkpxVElsampMZVdSNUI2dWg4N2x1czY0aFgydzZkcWk0TFBqR2N0Y05FYlJRb1BR?oc=5","date":"2025-10-20","type":"pipeline","source":"koreabiomed.com","summary":"[ESMO 2025] Enhertu outperforms Kadcyla in HER2-positive early breast cancer - koreabiomed.com","headline":"[ESMO 2025] Enhertu outperforms Kadcyla in HER2-positive early breast cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBCY0k5Y29hWW1GV2VqNHkxT203MzAtdHA4X3pONWNaVTVqLVYzNnZVb1B0dWpRdWNsbldFeWFWdnBicHNCV0JrUUtxWFhmakZ4RzJ6XzY0c3RvUVZJcGhOY3l1YVNKdHB5RGVKOXhR0gFyQVVfeXFMTkhTbURmNUxaNjA0bk5ibEdDc01FTjRBaURyV0ZhREcwZ2xrekRzRDhONndBMGlBQWQ1dkZGcEE5MURZeVVYZ2tLTWZZRHE1X19ZZ0htVGZiZDctbkF0dEhJck1oWm82U3Iycm1udXkxRHdR?oc=5","date":"2025-10-20","type":"pipeline","source":"koreabiomed.com","summary":"[ESMO 2025] Kisqali adjuvant therapy maintains efficacy at 5th year - koreabiomed.com","headline":"[ESMO 2025] Kisqali adjuvant therapy maintains efficacy at 5th year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQNGVvTGdyV0IzMmRhRG5QZVI5ek1LdjA1RXFLZm1BZ25kczVmTzVSUU9xeU1KUGEzM3FTV3VNcmNqWFFYcE91V3ZKZlpHeGNpQ0s2bjl4N240YjZsTkxlZElmeDVzWG1aUjdQX2ctbVZOck9UNk43cl81RDlpZHZlVnlHXzFuTThvcXppZEtVVlhERWxqVVg1VzRCamJhUWpOMC1CTUV1WUlLcm45RFJaODM3ajVhTWtCeF9EWEpfdlhjUDE1a1FwVHdn?oc=5","date":"2025-08-19","type":"pipeline","source":"OncLive","summary":"Chemo-Free Combination of Ribociclib/Trastuzumab/Letrozole Shows PFS Benefit in HR+/HER2+ Breast Cancer - OncLive","headline":"Chemo-Free Combination of Ribociclib/Trastuzumab/Letrozole Shows PFS Benefit in HR+/HER2+ Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5UZGtPRGlvcTZvUlNIYXlqdlhzRnFOX013NGFUUGxsWFRlZXd0cHZ6UFlIVU9WaVd4Q1hGMHUyVTdrU2JaSHNtYW9VYWhHRngwcFlramZUNTJlUUhxdTF1a3BlUXEtU0FiWjEzYXZB0gFyQVVfeXFMTTB0LUxlUjNIMTRLaGFNc2gtZGExVnpuSkphaUV0TmE5b2QxNVhFMGxqcFdQUHdHOUZLcG52eFdqV3YwZ09SZFY2UjlOeGo1aHR5ZUdpUkY5eDY0bDlla0JMRXIwMjZXZHdsQ3RDZW9SSTVn?oc=5","date":"2025-08-11","type":"pipeline","source":"koreabiomed.com","summary":"NGS, essential tool for breast cancer treatment, but Korea’s reimbursement barriers stall progress - koreabiomed.com","headline":"NGS, essential tool for breast cancer treatment, but Korea’s reimbursement barriers stall progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE4wUUNjYXByQUU4RkNBanFpQVhIQnlmTWpWOTRZb1oyODNsU0laSGgyajQ5bFBFY29NWHdDQTVKbW81bWEwdVNFQjFMWGFUY0FxS3pEem90eGtnel9QbldhRno1Ymp3ZzhpbnpjWmt30gFyQVVfeXFMTUJ0bFM2OXJKbFllTjdHWTdQTkVpczlOdXlMQTJzU1NYNUpSYjRIWTZad2M4TTlfMlBJNV9MNmF4UmVIMGpubUZaYUxlckNtMTNMMi1VeWw4SDFBU0I0QlBUWVpzaFhSUHdjN0twYWVsQTJn?oc=5","date":"2025-06-05","type":"pipeline","source":"koreabiomed.com","summary":"[ASCO 2025] ‘Treatment for relatively younger Korean breast cancer patients should better fit their characteristics’ - koreabiomed.com","headline":"[ASCO 2025] ‘Treatment for relatively younger Korean breast cancer patients should better fit their characteristics’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNVEo0amZCLWpvODdXS0pjczNnbDV1T0dITi1XdUQyVk0xNWRNR2o1anJWVUo4VmlqZGMzYkxoUU1aSDk1OU90UW4tUFlPMlVSM2hYbVBzR2hRa0FmRi1zM2QyOUxvS3Yxcm1ra2ZzcDE5V0F3LUFSR3FmWHF6cUswb003MWRKV1NhUmR3ZUJOMFpUY3lDeS1EWGNYZWJyMjhHWlpZRnYzMm5CZHdvWUZJNmVpU3FNWS1GSHNnekdiSE1vSkdEcVhOY0k2VEVzZ09UaUJFSkQ5V0VmSzkzMnQ1c3BSY3Q?oc=5","date":"2025-06-02","type":"trial","source":"prnewswire.com","summary":"Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine - prnewswire.com","headline":"Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE41QndoYXJINnBydDJqNDMzczVUU2VQTEoxeGJRZHpySnY3TE41T2xsbHNEbmRKVHpiOHB2Q2IzT1ktMEtCS29TV2JBQzhtbzhuRVBRTnh3SmJGTm9ITl9mUkhrTG1QQWZaRVpweVhB?oc=5","date":"2025-05-20","type":"pipeline","source":"KED Global","summary":"S.Korea’s Lunit installs breast cancer AI diagnostic tool at 200 US hospitals - KED Global","headline":"S.Korea’s Lunit installs breast cancer AI diagnostic tool at 200 US hospitals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5LZnVaUlJ6dlFzX3I2YzJPTk1wdkR0TUlrUEpSaC0xVnpLUVVJbU9tMWNVeTVWSUszUVlpbHF0VThnMXR4N1RjZzhhUUVSaDdsMW9NcVQ5cXBwc3l5WmJj?oc=5","date":"2024-09-12","type":"trial","source":"Nature","summary":"Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC | npj Breast Cancer - Nature","headline":"Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC |","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBJaHlpdHdjWUdzZWJCdzVOX3lqbDE2TDcxMEp5WUUtc1R5RmczX1c2TFVtb0RjUElTVzlxeE1mMENsbXBUUjFERTllUXNMTXNkRVdwMEgxbzVvUEhIZzFj?oc=5","date":"2024-06-02","type":"trial","source":"Nature","summary":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial - Nature","headline":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analys","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE50MklhdFBnUzBwTC1sZkNyekFxb2VCMUEtWThPcURxOWRiRWNxd2JlN2tqTkxVMmJOWGJDRXJDRFoySUxLcTJNYkJJZjBuWXJnOFJEblRFMWcySDY5QmtV?oc=5","date":"2024-06-01","type":"trial","source":"Nature","summary":"Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial | Nature Medicine - Nature","headline":"Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial | Nature Medicine","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}